Anu Puri, Ph.D.
Dr. Puri is developing cancer nanomedicine tools (including small molecule drugs and RNAi therapeutics) that are activated by light for on-demand drug release to improve cancer treatment of patients. She is also developing nanobiosensors for raid detection of pathogens in patient’s samples.
Dr. Puri’s research focuses on the unfolding mechanisms of entry pathways of enveloped viruses. Using cell biological, biophysical, biochemical approaches, she has studied the assemblies of molecular scaffolds of viral proteins and their receptors that are essential for infection of rhabdo, orthomyxo, paramyxo and retroviruses.
1) biomembranes, 2) membrane lipids (structure, function and analysis), 3) virology (virus-receptor interactions), 4) nanomedicine, 5) lipid-based drug delivery platforms, RNAi therapeutics
My area of research focuses on the mechanisms of entry pathways of enveloped viruses. Using cell biological, biophysical, biochemical approaches, I have studied the assemblies of molecular scaffolds of viral proteins and their receptors. Enveloped animal viruses deliver their genetic material to the cell by fusion of their membranes with those of the target cell. I have examined fusion mechanisms of members of rhabdo, orthomyxo, paramyxo and retrovirus family. My interest lies in elucidating the regulation of membrane fusion by plasma membrane lipid counter parts. The knowledge gained from my research has implications in the design of inhibitors of viral entry and the development of vaccines that prevent viral infection. Recently I have embarked upon the development of lipid-based nanoparticles for delivery of toxic drugs. I plan to develop liposomes bearing payload of drugs with imaging and targeting capabilities. My focus is to modify the building blocks of liposomes (phospholipids) to generate these particles, which will result in on-demand triggered release potential. My long-term goal is to develop these state-of the art liposomes compatible for delivery of anti-cancer agents to patients.
Phototriggerable Liposomes: Current Research and Future Perspectives (Invited Review).Pharmaceutics. 6: 41654, 2014. [ Journal Article ]
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).J Control Release. 153: 187-94, 2011. [ Journal Article ]
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion.J Virol. 78: 7360-8, 2004. [ Journal Article ]
Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment.J Virol. 64: 3824-32, 1990. [ Journal Article ]
- J Biol Chem. 263: 4749-53, 1988. [ Journal Article ]
Dr. Puri received her Ph.D. degree in chemistry from the Central Drug Research Institute, Lucknow, INDIA, studying the chemical synthesis of modified phospholipids and possible use of their liposomes in drug delivery. Currently she holds the Research Biologist position at the CCR RNA Biology laboratory, NCI-Frederick, NIH. Her research revolves around several themes including (a) Lipid-based nanoparticles for targeted delivery of cancer therapeutics including RNAi Therapeutics, (b) Stimuli-senstive nanomedicine for on-demand site-specific delivery of anti-cancer drugs and siRNAs to improve cancer therapies, (c) Development of nano-scale diagnostic tools for detection of pathogens and cancer biomarkers, and (d) Cell Biology of Viral Entry, and mechanisms of opportunistic infections in AIDS and related diseases.